Egypt: Generic Drug Prescribing Mandate Urged After Error

• A seven-year-old in Egypt suffered severe neurological symptoms after a pharmacy dispensed an epilepsy medication instead of a prescribed nutritional supplement due to a name confusion.
• The incident led to a lawsuit against the pharmacy and complaints to the Egyptian Drug Authority, Pharmacists Syndicate, and public prosecutor.
• Pharmacists advocate for a mandate requiring doctors to prescribe drugs by their generic names to prevent such errors, a measure also recommended by a 2024 prime ministerial directive.
• Doctors, however, resist this change, reportedly due to significant financial and professional incentives from pharmaceutical companies.

Pharmacists are now urgently calling for a national mandate requiring physicians to prescribe medications using their generic, non-proprietary names to mitigate such risks.

A seven-year-old girl in Zahraa al-Maadi, identified as Mecca, experienced a severe medical emergency following a pharmacy dispensing error. After visiting a doctor for a cold and sore throat, she was prescribed a nutritional supplement. Her family sent a photograph of the prescription to a local pharmacy for home delivery, with the medication arriving around 11:30 pm. Following Mecca's ingestion of a 6-ml dose, her mother, Samia, observed symptoms resembling paralysis.

Samia immediately sought medical attention for her daughter, first at the Poison Control Center, which declined admission. Several other hospitals also refused care, informing Samia that since 24 hours had passed since the medication was administered, Mecca required the specialized care unit at Demerdash Hospital's intensive care unit. Mecca remained unwell for a day and a half, unable to move her hands, legs, or eyes, a condition that persisted for four days before she eventually recovered. The family subsequently initiated a lawsuit against the pharmacy and lodged formal complaints with the Egyptian Drug Authority, the Pharmacists Syndicate, and the public prosecutor.

The dangerous incident involving Mecca stemmed from a critical error in drug identification, where the pharmacist mistakenly dispensed an epilepsy medication instead of the intended nutritional supplement. According to Mecca's mother, the confusion arose from a two-letter difference in the drug names. The prescribed drug, Respidep, a nutritional supplement containing Acetylcysteine, was confused with Risperdal, an antipsychotic medication containing Risperidone, which is used to treat certain psychiatric and neurological disorders. The similarity between the trade names Respidep and Risperdal was a direct cause of the mix-up.

Pharmacy sector professionals and officials from the Pharmacists Syndicate emphasize that Mecca's case is not an isolated incident. They report that similar dispensing errors, often involving just a two-letter difference between drug names, have occurred frequently, sometimes leading to the mistaken administration of neurological medications. An anonymous official from the Pharmacists Syndicate asserted that such a life-threatening situation would have been avoided had the generic name of the drug been used in the prescription. These experts contend that while individual investigations are crucial for accountability, they fail to address the underlying systemic issue that allows such dangerous mistakes to recur.

In response to these recurring dangers, pharmacists are advocating for a fundamental shift in prescribing practices: a mandate requiring physicians to prescribe medications by their generic, non-proprietary names. This measure, they argue, would significantly reduce the likelihood of pharmacists confusing the commercial names of popular drugs, thereby enhancing patient safety. This demand has been formally presented to the Health Ministry by pharmacists.

The call for mandatory generic drug prescribing aligns with a recommendation already put forth in a 2024 prime ministerial directive. Despite this official recommendation and the clear safety benefits, doctors have expressed reluctance to adopt this practice. Sources indicate that this resistance is largely driven by substantial financial and professional incentives provided by pharmaceutical companies, stemming from marketing arrangements that generate billions in revenue.

The legal and regulatory framework surrounding drug dispensing in Egypt is under scrutiny following Mecca's case. The family's complaints to the Egyptian Drug Authority, which is responsible for pharmacy inspections, alongside the Pharmacists Syndicate and the public prosecutor, underscore the multi-faceted nature of liability in such incidents. While these complaints are vital for establishing accountability for the specific error, industry professionals argue that a broader regulatory change is necessary to prevent future occurrences.

The ongoing debate highlights the tension between current prescribing practices and the need for enhanced patient safety. The push for an Egypt generic drug prescribing mandate, supported by a prime ministerial directive, suggests a potential shift in regulatory policy. However, the reported unwillingness of medical practitioners to comply, influenced by pharmaceutical company incentives, presents a significant hurdle to implementing a comprehensive solution that could mitigate Egyptian drug dispensing liability and reduce pharmacist error in Egypt.

Lawyers should advise pharmacies and healthcare providers in Egypt on potential increased liability for drug dispensing errors, particularly if brand-name prescribing persists. They must also monitor the ongoing push for mandatory generic drug prescribing, as a new directive or regulation would significantly alter compliance requirements and risk exposure for medical professionals and pharmaceutical companies.

Source: Original reporting via Mada Masr